

## Supplementary material

**Supplementary Table 1** Total EREFS (IQR) at first diagnosis, 60-71 months, and last follow-up in the Tx and NT groups.

<b>All</b>	<b>Tx group (n = 14)</b>	<b>NT group (n = 22)</b>
First diagnosis	3 (2-5)	3 (3-4)
60-71 months	0 (0-4)	2 (1-3)
Last follow-up	1 (0-2.25)	1.5 (0.75-3)
<b>Diffuse type</b>	<b>Tx group (n = 10)</b>	<b>NT group (n = 7)</b>
First diagnosis	4 (2-5)	4 (4-5)
60-71 months	0 (0-2.5)	2 (1-5)
Last follow-up	1 (0-3.25)	3 (1-4)
<b>Localized type</b>	<b>Tx group (n = 4)</b>	<b>NT group (n = 15)</b>
First diagnosis	3 (2.25-3)	3 (3-3)
60-71 months	0.5 (0-1.75)	1 (1-2)
Last follow-up	1 (0.25-1)	1 (0-3)

Tx, PPI/PCAB treatment; NT, no treatment; PPI, proton pump inhibitor; PCAB, potassium competitive acid blocker; EREFS, EoE endoscopic reference score; IQR, interquartile range.

## Supplementary material

**Supplementary Table 2** Number of patients showing endoscopic remission (total EREFS  $\leq 2$ ) and non-remission (total EREFS  $>3$ ) at each follow-up period.

Treatment group		Tx group		NT group	
		Diffuse type (n = 10)	Localized type (n = 4)	Diffuse type (n = 7)	Localized type (n = 15)
Endoscopic phenotype					
Timing of follow-up endoscopy	First diagnosis	3/7 (0)	1/3 (0)	0/7 (0)	3/12 (0)
	0-11 months	5/2 (3)	2/2 (0)	2/2 (3)	7/1 (7)
	12-23 months	2/7 (1)	3/1 (0)	4/3 (0)	10/3 (2)
	24-35 months	6/2 (2)	3/1 (0)	1/4 (2)	6/3 (6)
	36-47 months	3/5 (2)	4/0 (0)	3/4 (0)	9/4 (2)
	48-59 months	3/4 (3)	4/0 (0)	2/4 (1)	10/2 (3)
	60-71 months	6/3 (1)	4/0 (0)	4/3 (0)	12/3 (0)
	72-83 months	5/0 (5)	3/0 (1)	2/2 (3)	6/1 (8)
	84-95 months	4/1 (5)	2/0 (2)	2/4 (1)	6/1 (8)
	96-107 months	4/0 (6)	1/0 (3)	1/1 (5)	5/1 (9)
	108-119 months	1/1 (8)	1/0 (3)	1/0 (6)	1/1 (13)
	120-131 months	1/1 (8)	1/0 (3)	0/0 (7)	2/0 (13)

Tx, PPI/PCAB treatment; NT, no treatment; PPI, proton pump inhibitor; PCAB, potassium competitive acid blocker; EREFS, EoE endoscopic reference score.

The numbers in the table sequentially indicate the number of patients with EREFS  $\leq 2$ / EREFS  $> 3$ . The numbers within parentheses represent the numbers of patients who did not undergo follow-up endoscopy.

## Supplementary material

**Supplementary Fig. 1** IEC assessed by esophageal biopsies at first diagnosis, 60 to 71 months, and last follow-up was separately shown for the PPI/PCAB treatment (Tx) group and the no treatment (NT) group and further for the endoscopic phenotypes. The timing of the last follow-up varies from patient to patient. Tx, PPI/PCAB treatment; NT, no treatment; IEC, intraepithelial eosinophil count.

